On that note, let's dive in and investigate how the bull thesis for buying Vertex stock just got even stronger. Read More: ...

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $478.09, denoting a -1.02% change from the preceding trading day.

Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with groundbreaking discoveries, cutting-edge research, and influential biotech ...

On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...

Those around that level are, disproportionately, relatively small and risky companies whose prospects don't look all that ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...